Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

White Plains, New York 10604


Purpose:

This is a phase 1b study for safety and tolerability of bevacizumab(Avastin)administered into the tumor resection cavity in subjects with Glioblastoma Multiforme (GBM) at first recurrence.


Criteria:

Inclusion Criteria: 1. Recurrent Glioblastoma 2. At least 12 weeks expected survival (KPS >60) 3. 18 years of age or older 4. Able and willing to participate Exclusion Criteria: 1. Any prior diagnosis of any other cancer or other concurrent malignancy. 2. Planned use or current use of other investigation therapy. 3. Systemic autoimmune disease 4. HIV positive 5. Concurrent life threatening disease 6. Impaired organ function 7. Active infection 8. Inadequately controlled hypertension 9. Congestive heart failure 10. Myocardial infection/unstable angina within 6 months 11. Stroke within 6 months 12. Pheripheral vascular disease 13. History of abdominal fistula/gastrointestinal performation 14. Non-healing wound 15. Coagulation disease 16. Known allergy to study treatments 17. Pregnant or lactating


NCT ID:

NCT01526837


Primary Contact:

Principal Investigator
John Abrahams, MD
Brain & Spine Surgeons of New York


Backup Contact:

N/A


Location Contact:

White Plains, New York 10604
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.